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Abstract
There is no practical predictive model for the diagnosis of gastrointestinal stromal tumors (GISTs). To establish a practical predictive
model for the diagnosis of subepithelial lesions in the stomach, we reviewed patients with GISTs (n=89), schwannomas (n=7), and
leiomyomas (n=28).
The tumor was more frequently found along the gastric cardia in the leiomyoma group (57.1%) than in the GIST/schwannoma
group (2.1%, P< .01). Contrast enhancement (57.3% vs 0%, P< .01) and intra-tumoral necrosis (34.4% vs 0.0%, P< .01) were
more frequently observed in the GIST/schwannoma group than in the leiomyoma group. On endoscopic ultrasonography, 58.3% of
GISTs/schwannomas showed uneven echogenicity, whereas the echogenicity was uneven in 21.4% of leiomyomas (P< .01). There
were no differences between the tumor color and the presence or absence of ulcer formation, tumor bleeding, irregularity of the tumor
margin, cystic spaces, and hyperechoic spots between the 2 groups. Based on these results, we developed a 2-step diagnostic
algorithm for GISTs/schwannomas. The first step comprises 1 endoscopic feature: a cardiac or non-cardiac location. Tumors with a
cardiac location were judged as leiomyomas and those with a non-cardiac location were judged as GISTs/schwannomas, with
96.9% sensitivity and 57.1% specificity for GIST/schwannoma diagnosis. The second step comprises a combination of endoscopic
(non-cardiac location), radiologic (positive contrast enhancement and intra-tumoral necrosis), and endosonographic (uneven
echogenicity) features for a total of 4 points. We assigned 1 point to each feature. Tumors with scores of 2 to 4 were judged as GISTs/
schwannomas, with 81.3% sensitivity and 92.9% specificity for GIST/schwannoma diagnosis.
Our predictive model will be a practical guide for the management of gastric subepithelial lesions.
Abbreviations: CT = computed tomography, GIMTs = gastrointestinal mesenchymal tumors, GISTs = gastrointestinal stromal
tumors.
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1. Introduction
Various tumors occur as subepithelial lesions in the stomach,
including gastrointestinal stromal tumors (GISTs), leiomyomas,
lipomas, granular cell tumors, ectopic pancreatic tissue, and
neuroendocrine tumors.[1,2] Although these lesions are generally
identified during esophagogastroduodenoscopy, prompt diagno-
sis is challenging because the surface of the tumor is usually
covered with intact gastric mucosa and acquisition of the tumor
tissue by endoscopic biopsy is difficult. Therefore, imaging
findings on computed tomography (CT), endoscopic ultrasonog-
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raphy, and positron emission tomography are important for
gastric subepithelial lesions.[3,4]
In general, subepithelial lesions in the stomach are unexpect-
edly detected during esophagogastroduodenoscopy for screening
purposes or symptoms unrelated to the subepithelial lesion. Thus,
a large number of gastric subepithelial lesions are diagnosed in
primary healthcare institutions, where CT and/or endoscopic
ultrasonography are unavailable. In these settings, physicians
must decide based on the endoscopic features alone to refer the
patients to secondary or tertiary care centers for further
investigation of gastric subepithelial lesions. Although endoscop-
ic features of GISTs and other subepithelial lesions have been
investigated, there is no practical predictive model for the
diagnosis of GISTs based on endoscopic features alone. The
purpose of this study was to develop a 2-step diagnostic
algorithm for differentiating GISTs and schwannomas from
leiomyomas: a screening method using endoscopic features as the
first step and a scoring system combining endoscopic, radiologic,
and endosonographic features as the second step.
2. Methods
2.1. Patients
In this study, we enrolled patients with gastrointestinal
mesenchymal tumors (GIMTs) in the stomach that were
pathologically diagnosed between August 1994 and September
2021 at Okayama University Hospital. Histological diagnosis
was based on morphologic and immunophenotypic analyses of
endoscopically biopsied specimens, endoscopic ultrasound-fine
needle aspiration specimens, or surgically excised specimens. We
excluded patients with a GIMT that was unrecognizable during
esophagogastroduodenoscopy or CT performed pre-operatively
and those incidentally identified postoperatively because their
location and morphologies were not evaluable. Ultimately, 124
patients were included in this study. Clinical data regarding
endoscopic, radiological, and biological examinations were
obtained from retrospectively reviewed clinical records.
This study was approved by the Ethical Committee of
Okayama University Hospital and adhered to the Declaration
of Helsinki.
2.2. Analysis
Based on the pathological diagnosis, the patients were divided
into GIST/schwannoma and leiomyoma groups. To identify
factors that differentiate GISTs/schwannomas from leiomyomas,
we evaluated patient sex, age at diagnosis, tumor location and
color, internal echogenicity, presence or absence of ulceration on
the surface, irregular morphology, contrast enhancement, intra-
tumoral necrosis, tumor bleeding, and cystic degeneration.
Location, color, morphology, and presence or absence of
ulceration on the surface were evaluated using esophagogas-
troduodenoscopy images. The location of the GIMT was
dichotomized as pericardiac orifice or non-cardial. We defined
tumors that adjoined more than one-fourth of the circumference
of the cardiac orifice as having a pericardiac orifice location
(Fig. 1A and B). Conversely, tumors separated from the cardiac
orifice (Fig. 1C) and those adjoining less than one-fourth of the
circumference of the cardiac orifice (Fig. 1D) were defined as non-
cardial. Internal echogenicity, cross-section margins, and the
presence or absence of cystic degeneration were investigated
using endoscopic ultrasonography. CT images were used to
identify contrast enhancement, intra-tumoral necrosis, tumor
bleeding, and irregularity of the tumor margin. We defined
positive contrast enhancement as the presence of a clearly
enhanced area within the lesion in the arterial phase that
contrasted with the normal surrounding structures.
2.3. Statistical analysis
For comparisons of the 2 groups, statistical analyses including t
tests, chi-square tests, and F-tests were performed using JMP Pro
14.0.0 software (SAS Institute, Cary, NC). Statistical significance
was set at P< .05.
3. Results
3.1. Differences between the GIST/schwannoma and
leiomyoma groups
Histologically, 89 patients were diagnosed with GISTs, 7 patients
were diagnosed with schwannomas, and 28 patients were
diagnosed with leiomyomas. GISTs were diagnosed using
endoscopic ultrasound-fine needle aspiration (n=47), surgical
excision (n=37), or endoscopic biopsy (n=5). All patients with
schwannomas were diagnosed using endoscopic ultrasound-fine
needle aspiration (n=7). Leiomyomas were diagnosed using
endoscopic ultrasound-fine needle aspiration (n=15), surgical
excision (n=10), or endoscopic biopsy (n=3). Thus, the GIST/
schwannoma and leiomyoma groups comprised 96 and 28
patients, respectively. The patients’ backgrounds and character-
istics are shown in Table 1. There were 41 men and 55 women in
the GIST/schwannoma group and 15 men and 13 women in the
leiomyoma group (P= .21). The age at the time of diagnosis of
GISTs/schwannomas was significantly higher than that of
leiomyomas (mean, 67.7 vs 51.2years; P< .01).
Representative images of GISTs are shown in Figure 2, and
those of leiomyomas are shown in Figure 3. The mean tumor size
of GISTs/schwannomas (mean, 34.7mm; range, 7–140mm) was
significantly larger than that of leiomyomas (mean, 27.0mm;
range, 6–63mm; P< .05). Esophagogastroduodenoscopy was
not performed prior to surgical resection in 1 patient with a GIST.
Thus, location, color, and ulceration were not evaluated in this
patient. The tumor was located around the gastric cardia in 2
patients with a GIST/schwannoma (2.1%) and in 16 patients
with a leiomyoma (57.1%, P< .01). With respect to the color of
Figure 1. Tumors defined as having a pericardiac orifice location were those
that adjoinedmore than one-fourth of the circumference of the cardiac orifice (A
and B). Conversely, tumors separated from the cardiac orifice (C) and those
adjoining less than one-fourth of the circumference of the cardiac orifice (D)
were defined as non-cardial.
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the tumor, redness was observed in 8 patients with a GIST/
schwannoma (8.3%) and in 4 patients with a leiomyoma (14.3%,
P= .47). Ulcer formation was observed in 16 patients with a
GIST/schwannoma (16.7%) and in 2 patients with a leiomyoma
(7.1%, P= .17).
CT was performed in 85 patients with GISTs/schwannomas
and 18 patients with leiomyomas. Contrast enhancement was
positive in 55 patients with GISTs/schwannomas (57.3%),
whereas no patients with leiomyomas showed contrast enhance-
ment (0.0%, P< .01). Intra-tumoral necrosis was observed in 33
patients with GISTs/schwannomas (34.4%) and in none of the
patients with leiomyomas (0.0%, P< .01). None of the patients
with leiomyomas had tumor bleeding or irregularity of the tumor
margin (0.0%). In contrast, tumor bleeding was observed in 8







Figure 2. Representative images of gastric gastrointestinal stromal tumors. An
88-year-old woman had a large, multinodular subepithelial lesion in the lesser
curvature of the body, showing a non-cardial location (A). There was no
redness on the tumor surface. Endoscopic ultrasonography showed uneven
hyperechogenicity in the tumor, surrounded by a hypoechoic halo (B, arrows).
A large tumor, shown on a computed tomography image (C, arrows), was
accompanied by avascular, cystic areas with fluid levels of contrast
enhancement (asterisks), suggesting intra-tumoral necrosis and bleeding.
The tumor also had a calcifying area (arrowhead). A 37-year-old woman had a
subepithelial tumor with ulceration in the lesser curvature of the body (D).
A B
DC
Figure 3. Representative images of gastric leiomyomas. A 73-year-old woman
had a subepithelial tumor around the cardia, that is, a pericardiac orifice location
(A). The mucosa covering the tumor was reddish. On endoscopic ultrasono-
graphy, a tumor with low echoic, even echogenicity was observed (B). On
contrast-enhanced computed tomography, the tumor was shown to be
hypovascular and there was no intra-tumoral necrosis (C). A 73-year-old woman
had a gastric leiomyoma, which was located along the gastric cardia (D).
Table 1





n (%) P value
Sex .21
Men 41 (42.7) 15 (53.6)
Women 55 (57.2) 13 (46.4)
Age (yrs, mean ± SD) 67.7±12.8 51.2±15.9 <.01
Tumor size (mm, mean ± SD) 34.7±26.5 27.0±13.9 <.05
Location <.01
Pericardiac orifice 2 (2.1) 16 (57.1)
Not around the cardia 93 (96.9) 12 (42.9)
Undetermined 1 (1.0) 0 (0.0)
Color .47
Reddish 8 (8.3) 4 (14.3)
Other than reddish 84 (87.5) 24 (85.7)
Undetermined 4 (4.2) 0 (0.0)
Ulceration .17
Present 16 (16.7) 2 (7.1)
Absent 76 (79.2) 25 (89.3)
Undetermined 4 (4.2) 1 (3.6)
Vascularity on CT <.01
Hypervascular 55 (57.3) 0 (0.0)
Hypovascular 30 (31.3) 17 (60.7)
Undetermined 11 (11.5) 11 (39.3)
Intra-tumoral necrosis on CT <.01
Present 33 (34.4) 0 (0.0)
Absent 52 (54.2) 18 (64.3)
Undetermined 11 (11.5) 10 (35.7)
Tumor bleeding .34
Present 8 (8.3) 0 (0.0)
Absent 76 (79.2) 18 (64.3)
Undetermined 12 (12.5) 10 (35.7)
Irregularity of the tumor margin .59
Present 6 (6.3) 0 (0.0)
Absent 79 (82.3) 18 (64.3)
Undetermined 11 (11.5) 10 (35.7)
Echogenicity on EUS <.01
Uneven 56 (58.3) 6 (21.4)
Even 10 (10.4) 13 (46.4)
Undetermined 30 (31.3) 9 (32.1)
Cystic space on EUS .51
Present 14 (14.6) 2 (7.1)
Absent 52 (54.2) 17 (60.7)
Undetermined 30 (31.3) 9 (32.1)
Hyperechoic spot on EUS .78
Present 21 (21.9) 5 (17.9)
Absent 45 (46.9) 14 (50.0)
Undetermined 30 (31.3) 9 (32.1)
CT= computed tomography, EUS= endoscopic ultrasonography, GIST=gastrointestinal stromal
tumor, SD= standard deviation.
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patients with GISTs/schwannomas (6.3%, P= .59). Statistically,
contrast enhancement and intra-tumoral necrosis were more
frequently observed on CT in the GIST/schwannoma group than
in the leiomyoma group.
Endoscopic ultrasonography was performed in 66 patients
with GISTs/schwannomas and 19 patients with leiomyomas. On
endoscopic ultrasonography, 56 GISTs/schwannomas showed
uneven echogenicity (58.3%), whereas echogenicity was uneven
in 6 leiomyomas (21.4%, P< .01). In contrast, cystic spaces were
observed in 14 patients with GISTs/schwannomas (14.6%) and 2
patients with leiomyomas (7.1%, P= .51). There were no
differences between the hyperechoic spots in GISTs/schwanno-
mas and leiomyomas (21 vs 5, P= .78).
3.2. Screening based on an endoscopic feature
As described above, non-cardiac location is the sole significant
endoscopic feature that could be suggestive of GISTs/schwanno-
mas. Thus, we used this feature to establish a predictive model to
identify patients with GISTs/schwannomas (Fig. 4). Tumors with
a non-cardiac location were judged as GISTs/schwannomas, and
those with a cardiac location were judged as leiomyomas, with
96.9% sensitivity and 57.1% specificity for GIST/schwannoma
diagnosis.
3.3. Scoring system based on combination of endoscopic,
radiologic, and endosonographic features
In addition to the endoscopic features of non-cardiac location
(feature 1), the CT features of positive contrast enhancement
(feature 2) and intra-tumoral necrosis (feature 3), as well as
endoscopic ultrasonography features of uneven echogenicity
(feature 4), were more frequently observed in patients with
GISTs. Consequently, we assigned 1 point to each feature. The
overall score was calculated based on the number of these 4
features (Fig. 4). Tumors with scores of 0 to 1 were judged as
leiomyomas and those with scores of 2 to 4 were judged as GISTs/
schwannomas, with 81.3% sensitivity and 92.9% specificity for
GIST/schwannoma diagnosis.
In the present study, endoscopic ultrasound-fine needle
aspiration was performed in 55 patients with GISTs/schwanno-
mas and 16 patients with leiomyomas. According to the scoring
system based on a combination of endoscopic, radiologic, and
endosonographic features, 14 of the 16 patients with leiomyomas
(87.5%) had a score of 0 to 1, while 53 of the 55 patients with
GISTs/schwannomas (96.4%) had a score of 2 to 4. Thus,
endoscopic ultrasound-fine needle aspiration might have been
deferred in 16 patients, provided that the scoring system was
applied, with a 94.4% accuracy for leiomyoma diagnosis.
4. Discussion
Among GIMTs, GISTs and leiomyosarcomas essentially require
surgical resection owing to their malignant nature. Although
gastric schwannomas are slow-growing tumors, some researchers
recommend surgical resection as they may become malignant.[5]
In contrast, all gastric leiomyomas are virtually benign; thus, they
can be followed-up without invasive treatment. Consequently,
the differentiation of gastric leiomyomas from other GIMTs is
important to ensure appropriate clinical management.[6]
In this study, we developed a 2-step diagnostic algorithm for
differentiating gastric GISTs and schwannomas from leiomyo-
mas. The first step comprises an endoscopic feature, and the
second step is a scoring system combining endoscopic, radiologic,
and endosonographic features. As described above, most gastric
subepithelial lesions are unexpectedly identified during esoph-
agogastroduodenoscopy.[7,8] As CT and endoscopic ultrasonog-
raphy are generally not accessible in primary healthcare
institutions, the first step based on an endoscopic feature
(cardiac/non-cardiac location) is probably useful in these settings
to decide whether patients should referred to a secondary or
tertiary care institution for further investigation. Although the
specificity for GISTs/schwannoma diagnosis is relatively low
(57.1%) in the first step based on an endoscopic feature, it
improved to 92.9% when combined with radiologic and
endosonographic features. Thus, a scoring system based on a
combination of endoscopic, sonographic, and radiologic features
(second step) may be useful as a predictive model for the
diagnosis of GISTs/schwannomas in secondary or tertiary care
institutions.
In actual clinical settings, we noticed that gastric leiomyomas
predominantly arise in the esophagogastric junction, whereas
gastric GISTs and schwannomas occur in other areas of the
stomach. In particular, leiomyomas often “surround” the cardiac
orifice. Therefore, in this study, we defined tumors that adjoined
more than one-fourth of the circumference of the cardiac orifice
as having a pericardiac orifice location (Fig. 1A and B). According
to this criterion, 57.1% of leiomyomas but only 2.1% of GISTs/
schwannomas occurred in the pericardiac orifice location. Such
differences between the location of GISTs and leiomyomas have
been reported previously.[9,10] In this context, the first step based
on endoscopic features is reasonable for screening leiomyomas
from further investigations. Our approach may also be beneficial
from an econometric standpoint. In patients who were classified





























Figure 4. A screening method based on an endoscopic feature (first step) and
a scoring system based on a combination of endoscopic, radiologic, and
endosonographic features (second step). CT=computed tomography, EUS=
endoscopic ultrasonography, GIST=gastrointestinal stromal tumor.
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ultrasonography can be omitted, and these patients are
periodically followed-up by esophagogastroduodenoscopy
alone. However, the appropriate interval between follow-up
endoscopy examinations should be elucidated. Meanwhile,
patients who were classified under the GIST/schwannoma group
in the second step should undergo pathological diagnosis, such as
endoscopic ultrasound-fine needle aspiration.
In the present study, the mean age at the time of diagnosis of
GIST/schwannoma was 67.7years, which was significantly
higher than that of leiomyoma (51.2years). This observation
of older age in patients with a GIST has been reported previously.
Liu et al[10] reported that the mean age of patients with a gastric
GIST diagnosis was 44.5years and that of patients with a gastric
leiomyoma diagnosis was 40.1years. The authors proposed a
scoring method for the diagnosis of GISTs using 7 clinical and CT
features, including older age (>49years), non-cardiac location,
irregular margin, lower attenuation on unenhanced images (43
HU), heterogeneous enhancement, necrosis, and absence of
enlarged lymph nodes. A cutoff score of ≥4 versus<4 provided a
sensitivity of 100% and specificity of 72%. A scoring system for
differentiating GISTs from non-GISTs using clinical and CT
features has been reported by other authors. For instance, Yin
et al[11] proposed 8 features consisting of older age (>46.5years),
tumor long diameter (>4.5cm), heterogeneous enhancement,
high degree of enhancement, mean CT attenuation >69.2 HU,
presence of intra-lesional low attenuation and surface ulceration,
and absence of calcification. The presence of at least 4 of these 8
features had a sensitivity of 76.7% and specificity of 76.5% for
differentiating GISTs from leiomyomas.
Endoscopic ultrasonography is also reportedly useful for GIST
diagnosis.[12–14] Kim et al[15] reported that uneven echogenicity,
hyperechoic spots, a marginal halo, and higher echogenicity than
the surrounding muscle layer were more frequently observed on
endoscopic ultrasonography in GISTs than in leiomyomas.
Lesions with at least 2 of these features provided a sensitivity of
89.1% and a specificity of 85.7% for predicting GISTs. The
round shape and irregular margin of the lesion are also
endoscopic ultrasonography features suggestive of GISTs.[16]
In the present study, we incorporated CT features of positive
contrast enhancement and intra-tumoral necrosis and an
endoscopic ultrasonography feature of uneven echogenicity as
items for the scoring system, as statistically significant differences
were observed in these features between GISTs and non-GISTs.
Although it may be possible to increase the accuracy of our
scoring system by adding other features characteristic of GISTs,
this concept requires further investigation.
Tumor size is generally important in the management of gastric
subepithelial lesions. For example, according to the clinical
practice guidelines for GIST in Japan, gastric subepithelial lesions
less than 2cm in size without malignant findings, such as
ulceration, irregular margins, and rapid growth in endoscopic
examinations can be followed-up by esophagogastroduodeno-
scopy every other year or every 2years.[17] In contrast, the
representative opinion with respect to the tumor behavior of the
GIST is that all GISTs should be considered to have a malignant
potential, with the possible exception of very small tumors
measuring less than 1cm.[18] Therefore, we consider that tumors
with features suggestive of GISTs should be further investigated
by CT and endoscopic ultrasonography, irrespective of tumor
size. However, since only 2 patients had GISTs of subcentimeter
in the present study, it should be elucidated how to deal with
gastric subepithelial lesions less than 1cm.
Tumor growth is also an important feature suggestive of
GISTs. However, we excluded this feature from our scoring
systems for the following 2 reasons. First, in the present study,
repeat esophagogastroduodenoscopy examinations were per-
formed on 75 lesions (data not shown). Enlargement of the tumor
was noted in 16 lesions, all of which were diagnosed as GISTs.
Although we incorporated the presence or absence of tumor
enlargement in the first step, it did not improve the accuracy of
GIST/schwannoma diagnosis, with 96.9% sensitivity and 57.1%
specificity. Second, elimination of the features of tumor growth
enables simplification of the screening test because it can be
applied even in the initial esophagogastroduodenoscopy
examination.
Our study has several limitations. First, this was a single-
center, retrospective study. Second, the number of enrolled
patients was relatively small, particularly those with leiomyomas,
owing to the low incidence of these tumors. In particular, because
of the missing values in our patient dataset, we could not perform
a multivariate analysis reliably. Third, a selection bias existed
because we enrolled patients with pathologically diagnosed
lesions. In the actual health care setting, the majority of gastric
subepithelial lesions are followed-up without histological
examinations. Lastly, although we proposed a 2-step diagnostic
algorithm for diagnosing GISTs/schwannomas, a validation
study was not conducted. Thus, to overcome these issues,
validation of our scoring system in a multicenter study with a
larger sample size is required.
In conclusion, we developed a 2-step diagnostic algorithm for
differentiating gastric GISTs and schwannomas from leiomyo-
mas. Although there are other predictive models for the diagnosis
of GIST in the literature, a possible advantage of our 2-step
diagnostic algorithm is that our model based on an endoscopic
feature (first step) can be used in primary healthcare institutions,
since it does not require a CT or an endoscopic ultrasonography.
Our report also highlights the non-cardiac location of GISTs and
schwannomas. The recognition of which is probably beneficial
for gastroenterologists to promptly diagnose gastric subepithelial
lesions. Although endoscopists often experience diagnostic
difficulties for gastric subepithelial lesions, we hope that our
predictive model will be a practical guide for the management of
these lesions in different levels of healthcare delivery systems.
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